Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Syphilis D013587 6 associated lipids
Hearing Disorders D006311 10 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Infant, Newborn, Diseases D007232 9 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Uterine Cervicitis D002575 3 associated lipids
Neutropenia D009503 15 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Urticaria D014581 13 associated lipids
Escherichia coli Infections D004927 17 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Harris JA et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. 1998 Pediatr. Infect. Dis. J. pmid:9802626
Adair CD et al. Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin. 1998 Obstet Gynecol pmid:9469269
García Callejo FJ et al. [Comparison of azithromycin, amoxicillin/clavulanic acid and cefaclor in the treatment of acute ENT infections]. 1998 Acta Otorrinolaringol Esp pmid:9707742
Kober MB and Mason BA Colonization of the female genital tract by resistant Ureaplasma urealyticum treated successfully with azithromycin. 1998 Clin. Infect. Dis. pmid:9709898
Langtry HD and Balfour JA Azithromycin. A review of its use in paediatric infectious diseases. 1998 Drugs pmid:9711451
Bianchi A et al. Kinetics of Chlamydia trachomatis clearance in patients with azithromycin, as assessed by first void urine testing by PCR and transcription-mediated amplification. 1998 Sex Transm Dis pmid:9713917
Karpov OI et al. [Comparative trial of 3-day azithromycin versus 10-day coamoxilav course efficacy in acute sinusitis]. 1998 Ter. Arkh. pmid:9644751
[6th München AIDS-Days. Azithromycin in HIV-associated opportunistic infections]. 1998 Internist (Berl) pmid:9648000
Griffith DE et al. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. 1998 J. Infect. Dis. pmid:9652431
Haye R et al. Azithromycin versus placebo in acute infectious rhinitis with clinical symptoms but without radiological signs of maxillary sinusitis. 1998 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9721958
Wirnsberger GH et al. Effect of antibiotic treatment with azithromycin on cyclosporine A-induced gingival hyperplasia among renal transplant recipients. 1998 Transplant. Proc. pmid:9723411
Blandizzi C et al. Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis. 1998 J. Antimicrob. Chemother. pmid:9700531
Denis A and Agouridas C Synthesis of 6-O-methyl-azithromycin and its ketolide analogue via Beckmann rearrangement of 9(E)-6-O-methyl-erythromycin oxime. 1998 Bioorg. Med. Chem. Lett. pmid:9873555
den Hollander JG et al. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. 1998 Antimicrob. Agents Chemother. pmid:9527789
Chey WD et al. Low- versus high-dose azithromycin triple therapy for Helicobacter pylori infection. 1998 Aliment. Pharmacol. Ther. pmid:9882036
Trevisani L et al. Evaluation of a new ultrashort triple therapy for Helicobacter pylori disease. 1998 Aliment. Pharmacol. Ther. pmid:9882037
Gascón A et al. Cryptosporidiosis in a haemodialysis patient with depressed CD4+ T cell count: successful treatment with azithromycin. 1998 Nephrol. Dial. Transplant. pmid:9829506
Sackoff J et al. Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care. 1998 J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. pmid:9833748
Hogan PA and Sheehan DJ Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997. 1998 Antimicrob. Agents Chemother. pmid:9835536
Mortensen JE et al. In vitro activity of oral antimicrobial agents against clinical isolates of Pasteurella multocida. 1998 Diagn. Microbiol. Infect. Dis. pmid:9554176
Hoppe JE and Bryskier A In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). 1998 Antimicrob. Agents Chemother. pmid:9559823
Clancy CJ and Nguyen MH The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. 1998 J. Antimicrob. Chemother. pmid:9511049
Oldfield EC et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. 1998 Clin. Infect. Dis. pmid:9524832
Fuentes F et al. Postanitbiotic and sub-MIC effects of azithromycin and isepamicin against Staphylococcus aureus and Escherichia coli. 1998 Antimicrob. Agents Chemother. pmid:9527796
Kashuba AD and Amsden GW Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. 1998 Antimicrob. Agents Chemother. pmid:9527816
Socan M Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. 1998 J Chemother pmid:9531077
Muhlestein JB et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. 1998 Circulation pmid:9495296
Woldtvedt BR et al. Possible increased anticoagulation effect of warfarin induced by azithromycin. 1998 Ann Pharmacother pmid:9496419
Champney WS and Burdine R Macrolide antibiotic inhibition of translation and 50S ribosomal subunit assembly in methicillin-resistant Staphylococcus aureus cells. 1998 Microb. Drug Resist. pmid:9818968
Seelis RE and Dohmen W [Short-term (6 days) eradication of Helicobacter pylori infection in the practice of a health insurance physician]. 1998 Dtsch. Med. Wochenschr. pmid:9487294
Thalhammer F et al. Azithromycin-related toxic effects of digitoxin. 1998 Br J Clin Pharmacol pmid:9489601
Wawer MJ et al. A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda. 1998 AIDS pmid:9677171
Goldstein EJ et al. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. 1998 Antimicrob. Agents Chemother. pmid:9593139
Spangler SK et al. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. 1998 Antimicrob. Agents Chemother. pmid:9593160
Turcinov T and Pepeljnjak S Azithromycin potency determination: optimal conditions for microbiological diffusion method assay. 1998 J Pharm Biomed Anal pmid:9682177
Pankuch GA et al. In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae. 1998 Antimicrob. Agents Chemother. pmid:9797225
Dagan R et al. Dynamics of pneumococcal nasopharyngeal colonization during the first days of antibiotic treatment in pediatric patients. 1998 Pediatr. Infect. Dis. J. pmid:9802628
Roblin PM and Hammerschlag MR In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. 1998 Antimicrob. Agents Chemother. pmid:9624507
Can antibiotics prevent heart disease? 1998 Harv Heart Lett pmid:9619136
Bass JW et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. 1998 Pediatr. Infect. Dis. J. pmid:9655532
Gruber F et al. Azithromycin compared with minocycline in the treatment of acne comedonica and papulo-pustulosa. 1998 J Chemother pmid:9876055
Négrel AD and Mariotti SP WHO alliance for the global elimination of blinding trachoma and the potential use of azithromycin. 1998 Int. J. Antimicrob. Agents pmid:9916898
Lacy MK et al. Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae. 1998 Int. J. Antimicrob. Agents pmid:9916901
Fera MT et al. Bactericidal activity of lansoprazole and three macrolides against Helicobacter pylori strains tested by the time-kill kinetic method. 1998 Int. J. Antimicrob. Agents pmid:9916902
Jakob-Sölder B et al. Treatment of pediatric patients with acute group A beta-hemolytic streptococcal tonsillopharyngitis. 1998 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9923529
Rothova A et al. Azithromycin for ocular toxoplasmosis. 1998 Br J Ophthalmol pmid:9924338
Apseloff G et al. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. 1998 J Clin Pharmacol pmid:9753212
Shih CM and Wang CC Ability of azithromycin in combination with quinine for the elimination of babesial infection in humans. 1998 Am. J. Trop. Med. Hyg. pmid:9790419
Carbon C Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. 1998 Clin. Infect. Dis. pmid:9675445
Greenblatt DJ et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. 1998 Clin. Pharmacol. Ther. pmid:9757151